

# VALUE-BASED HEALTHCARE CONFERENCE 2024

## 22-23 AUGUST 2024



### Feasibility and Implementation of an Out-of-Pocket Cost Calculator for Pre-Treatment Financial Counselling in Cancer Patients

Authors: Maggie WONG<sup>1</sup>, Zhi Yao CHAN<sup>2</sup>, Mei Yin QUEK<sup>3</sup>, Alexis KOH<sup>4</sup>, Li Jing Janelle CHAN<sup>3</sup>, Constance TEO<sup>2</sup>, Jinny FOO<sup>3</sup>, Cheng Ean CHEE<sup>1</sup>, Andrea WONG<sup>1</sup>, Samuel OW<sup>1</sup>, Joey TAY<sup>3</sup>, Vivian LUAH<sup>4</sup>, Xiao Shi SAW<sup>2</sup>, Yuet Peng WONG<sup>2</sup>, Meng Tuck LEE<sup>3</sup>, Jolene LEE<sup>3</sup>, Yen-Lin CHEE<sup>1</sup> and Wei-Ying JEN<sup>1</sup>

1 Department of Haematology-Oncology, National University Cancer Institute, Singapore

2 Division of Oncology Pharmacy, National University Cancer Institute, Singapore

**3 Operations & Administration, National University Cancer Institute, Singapore** 

4 Clinical Support Services – Medical Social Work, National University Cancer Institute, Singapore

#### AIM

ChemoCalc, a digital calculator for individualised Out-Of-Pocket estimates, was developed to streamline the financial counselling (FC) process for cancer patients, aiming to improve efficiency, accuracy and uptake.

	_		
egimen	Results	Export result	
egimen 1			
NUH RITUXIMAB + DOXORUBICIN + V ~	Input summary	~	
+ Add regimen	Patient Details	160cm, 60kg, 1.63m <sup>2</sup>	
	Subsidy Details	Subsidy Details Subsidised, Singapore Citizen, Pioneer Generation, \$2000 < PCHI ≤ \$3300 [50 %	
		& MAF Subsidy]	
atient Details	Additional Details	Generic or Biosimilar	
ight (cm) Weight (kg)			
160 60			

#### BACKGROUND

In Singapore's healthcare landscape, with the recent introduction of the Cancer Drug List (CDL), determining Out-Of-Pocket costs for cancer treatment is complex, involving multiple factors such as subsidy status, insurance coverage, residency status, drug subsidy tier and therapeutic indication. This complexity underscores the need for efficient and accurate financial counselling process.

#### METHODS

Developed by a multidisciplinary team from a Singapore tertiary cancer centre, ChemoCalc integrates data from various sources including the CDL, hospital formulary, chemotherapy protocols, and various national subsidy schemes. An algorithm was devised to calculate regimen-specific Out-Of-Pocket costs. Following development, ChemoCalc underwent usability testing and FC staff training. Data was collected pre- and postimplementation, focusing on feasibility outcomes (including demand, acceptability, practicality and integration) and implementation outcomes (including adoption, engagement, efficiency and accuracy.)


#### RESULTS

ChemoCalc, implemented from Aug to Sep 2022, demonstrated high uptake with 72 staff members utilizing it. On average, the prices of 2,484 regimens (mean 11 regimens/patient) were generated each month, with a total of 17,385 price estimates generated. Adoption and engagement rates among FC staff were both 100%.

ChemoCalc significantly improved FC accuracy from a baseline of 35% to

Subsidy Details Subsidy Status (?)	Regimen 1 breakdown         NUH RITUXIMAB + DOXORUBICIN + VINCRISTINE +         CYCLOPHOSPHAMIDE + PREDNISOLONE         Q21DAYS (R-CHOP)         Cycle length: 21 days	S973
Subsidised   Residency Status ⑦  Singapore Citizen	Final Out of Pocket Costs (Estimated)	Out of pocket \$376 per month
Additional Subsidies ⑦ Pioneer Generation	Pre-Subsidy (CDL Drugs) Subsidies MediShield Life ⑦	\$597 -\$448 -\$134
\$2000 < PCHI ≤ \$3300 [50 % SDL & MAF ∨ Additional Details	Net Amount Payable (CDL Drugs) MediSave ③	\$15 -\$15
Choice of Drug ⑦ Generic or Biosimilar	Subtotal: Out of Pocket (CDL Drugs) Other Drugs & Services ③	\$0 \$376
	Total: Estimated Out of Pocket	\$376 per month





95% (270% increase). Time spent computing Out-Of-Pocket costs reduced from a median of 8min (range 4.5–13) to 44s (range 15-20) for simple regimens, and 23min (range 15.5-44) to 1min (range 0.3-1.3) for complex regimens respectively. Its convenience and simplicity led to 100% uptake for pre-treatment FC.

#### CONCLUSION

The implementation of ChemoCalc was successful with 100% adoption rate and significantly improved FC efficiency and accuracy. Its adaptable algorithm can be tailored for implementation in diverse healthcare settings, promising benefits in streamlining financial processes and improving patient care coordination.

#### CONTACT

maggie.wong@mohh.com.sg

Figure 2: UI Logic

